Alterations in meibomian glands in patients treated with intensity-modulated radiotherapy for head and neck cancer

Sci Rep. 2021 Nov 17;11(1):22419. doi: 10.1038/s41598-021-01844-9.

Abstract

Patients undergoing intensity-modulated radiotherapy (IMRT) for head and neck cancer may have increased incidence of dry eye disease and the exact mechanism is unclear. The present study aims to assess tear film and meibomian gland (MG) features in patients who received IMRT for head and neck cancer not involving the orbital area. Twenty-seven patients (64.7 ± 9.8 years) and 30 age-matched controls (61.4 ± 11.0 years) underwent a comprehensive dry eye work-up. Compared to the control group, the patients had more lid margin abnormalities, and worse meibum quality. The MG loss, calculated as (tarsal area-MG area)/tarsal area, was higher in the patient group in both the upper (53.0 ± 12.0% vs. 35.1 ± 10.3%, p < 0.001) and lower lids (69.5 ± 12.6% vs. 48.5 ± 12.5%, p < 0.001). In the patient group, more MG loss in the lower lids correlated with worse meibum quality (r = 0.445, p = 0.029). In contrast, there was no significant difference in aqueous tear production level, measured with Schirmer test. Patients treated with IMRT for head and neck cancer seemed to have comparable lacrimal gland function to the controls despite more dry eye symptoms. However, the patients had MG functional and morphological changes, which may present a higher risk for developing dry eye disease.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dry Eye Syndromes / epidemiology*
  • Dry Eye Syndromes / etiology*
  • Female
  • Head and Neck Neoplasms / radiotherapy*
  • Humans
  • Incidence
  • Male
  • Meibomian Glands / pathology
  • Meibomian Glands / radiation effects*
  • Middle Aged
  • Radiation Dosage
  • Radiotherapy, Intensity-Modulated / adverse effects*
  • Risk Factors
  • Tear Gases
  • Tears

Substances

  • Tear Gases